High Tumoral STMN1 Expression Is Associated with Malignant Potential and Poor Prognosis in Patients with Neuroblastoma
暂无分享,去创建一个
T. Yokobori | S. Nobusawa | J. Hirato | K. Shirabe | Takahiro Shirakura | H. Okami | Bilguun Erkhem-Ochir | Gendensuren Dorjkhorloo | Hiroshi Saeki | Kenjiro Ogushi | Junko Hirato | Akira Nishi | Makoto Suzuki | Sayaka Otake
[1] Z. Shao,et al. Protein Phosphatase 1 Subunit PPP1R14B Stabilizes STMN1 to Promote Progression and Paclitaxel Resistance in Triple-Negative Breast Cancer , 2022, Cancer research.
[2] Frederick S. Vizeacoumar,et al. A Drug Repurposing Screen Identifies Fludarabine Phosphate as a Potential Therapeutic Agent for N-MYC Overexpressing Neuroendocrine Prostate Cancers , 2022, Cells.
[3] G. C. Chan,et al. Anti-GD2 Directed Immunotherapy for High-Risk and Metastatic Neuroblastoma , 2022, Biomolecules.
[4] W. Wang,et al. Transcriptome dynamics of hippocampal neurogenesis in macaques across the lifespan and aged humans , 2021, Cell Research.
[5] Wei Hu,et al. PTEN loss promotes oncogenic function of STMN1 via PI3K/AKT pathway in lung cancer , 2021, Scientific Reports.
[6] Zhe Zhang,et al. CARMA3 Transcriptional Regulation of STMN1 by NF-κB Promotes Renal Cell Carcinoma Proliferation and Invasion , 2021, Technology in cancer research & treatment.
[7] G. Goodall,et al. Stathmin levels alter PTPN14 expression and impact neuroblastoma cell migration , 2019, British Journal of Cancer.
[8] Dan Zhang,et al. Association of STMN1 with survival in solid tumors: A systematic review and meta-analysis , 2019, The International journal of biological markers.
[9] Yi-xuan Yang,et al. Stathmin gene silencing suppresses proliferation, migration and invasion of gastric cancer cells via AKT/sCLU and STAT3 signaling. , 2019, International journal of oncology.
[10] M. Madonna,et al. Update on neuroblastoma. , 2019, Journal of pediatric surgery.
[11] Zhou Wang,et al. STMN1, a prognostic predictor of esophageal squamous cell carcinoma, is a marker of the activation of the PI3K pathway. , 2018, Oncology reports.
[12] K. Shirabe,et al. High STMN1 Expression Is Associated with Tumor Differentiation and Metastasis in Clinical Patients with Pancreatic Cancer. , 2018, Anticancer Research.
[13] Y. Liu,et al. MiR-770 suppresses the chemo-resistance and metastasis of triple negative breast cancer via direct targeting of STMN1 , 2018, Cell Death & Disease.
[14] H. Kuwano,et al. Prognostic impact of stathmin 1 expression in patients with lung adenocarcinoma , 2017, The Journal of thoracic and cardiovascular surgery.
[15] H. Kuwano,et al. High STMN1 Expression is Associated with Cancer Progression and Chemo-Resistance in Lung Squamous Cell Carcinoma , 2017, Annals of Surgical Oncology.
[16] J. Horiguchi,et al. Stathmin1 expression is associated with aggressive phenotypes and cancer stem cell marker expression in breast cancer patients , 2017, International journal of oncology.
[17] H. Kuwano,et al. High stathmin 1 expression is associated with poor prognosis and chemoradiation resistance in esophageal squamous cell carcinoma. , 2017, International journal of oncology.
[18] T. Oyama,et al. High STMN1 level is associated with chemo-resistance and poor prognosis in gastric cancer patients , 2017, British Journal of Cancer.
[19] O. Fadare,et al. An immunohistochemical analysis of stathmin 1 expression in uterine smooth muscle tumors: differential expression in leiomyosarcomas and leiomyomas. , 2015, International journal of clinical and experimental pathology.
[20] X. Bian,et al. Systemic Delivery of MicroRNA-101 Potently Inhibits Hepatocellular Carcinoma In Vivo by Repressing Multiple Targets , 2015, PLoS genetics.
[21] H. Kuwano,et al. Stathmin1 regulates p27 expression, proliferation and drug resistance, resulting in poor clinical prognosis in cholangiocarcinoma , 2014, Cancer science.
[22] Jing Zhao,et al. c‐Myc‐mediated epigenetic silencing of MicroRNA‐101 contributes to dysregulation of multiple pathways in hepatocellular carcinoma , 2014, Hepatology.
[23] G. Blandino,et al. Gain-of-function mutant p53 downregulates miR-223 contributing to chemoresistance of cultured tumor cells , 2014, Oncogene.
[24] Wen-Ren Wu,et al. Overexpression of stathmin 1 confers an independent prognostic indicator in nasopharyngeal carcinoma , 2014, Tumor Biology.
[25] L. Yang,et al. RNAi-mediated stathmin suppression reduces lung metastasis in an orthotopic neuroblastoma mouse model , 2014, Oncogene.
[26] H. Feilotter,et al. Stathmin 1 is a potential novel oncogene in melanoma , 2013, Oncogene.
[27] M. Minden,et al. Suspected leukemia oncoproteins CREB1 and LYL1 regulate Op18/STMN1 expression. , 2012, Biochimica et biophysica acta.
[28] Sik Yoon,et al. Hedgehog signaling regulates proliferation of prostate cancer cells via stathmin1 , 2010, Clinical and Experimental Medicine.
[29] S. Kyo,et al. Stathmin, a microtubule regulatory protein, is associated with hypoxia-inducible factor-1alpha levels in human endometrial and endothelial cells. , 2009, Endocrinology.
[30] Barbara Hero,et al. The International Neuroblastoma Risk Group (INRG) classification system: an INRG Task Force report. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[31] Shushan Rana,et al. Stathmin 1: a novel therapeutic target for anticancer activity , 2008, Expert review of anticancer therapy.
[32] B. Hero,et al. Neuroblastoma , 2007, The Lancet.
[33] M. Kavallaris,et al. Neuronal-associated microtubule proteins class III beta-tubulin and MAP2c in neuroblastoma: role in resistance to microtubule-targeted drugs. , 2004, Molecular cancer therapeutics.
[34] Gudrun Schleiermacher,et al. Gene expression profiling of 1p35–36 genes in neuroblastoma , 2004, Oncogene.
[35] D. Stram,et al. Loss of heterozygosity at 1p36 independently predicts for disease progression but not decreased overall survival probability in neuroblastoma patients: a Children's Cancer Group study. , 2000, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[36] T. Nammoku,et al. Identification and initial characterization of stathmin by the differential display method in nerve growth factor-treated PC12 cells. , 1998, European journal of endocrinology.
[37] Rogier Versteeg,et al. Allelic loss of chromosome 1p as a predictor of unfavorable outcome in patients with neuroblastoma. , 1996, The New England journal of medicine.
[38] J. Strahler,et al. N-myc gene amplification in neuroblastoma is associated with altered phosphorylation of a proliferation related polypeptide (Op18). , 1990, Oncogene.